Compare MGYR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MGYR | ACOG |
|---|---|---|
| Founded | 1922 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.1M | 110.4M |
| IPO Year | 2021 | N/A |
| Metric | MGYR | ACOG |
|---|---|---|
| Price | $17.40 | $6.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 2.2K | ★ 36.9K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 26.83 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | $35.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.22 | $4.50 |
| 52 Week High | $20.00 | $10.88 |
| Indicator | MGYR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 45.09 |
| Support Level | $17.04 | $5.73 |
| Resistance Level | $17.99 | $6.59 |
| Average True Range (ATR) | 0.15 | 0.41 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 26.47 | 23.05 |
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.